NYSEAMERICAN:RNN - Rexahn Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.25 -0.13 (-9.42 %)
(As of 01/21/2019 02:49 AM ET)
Previous Close$1.25
Today's Range$1.17 - $1.65
52-Week Range$0.85 - $2.70
Volume2.09 million shs
Average Volume756,165 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer. Rexahn Pharmaceuticals, Inc. is based in Rockville, Maryland.

Receive RNN News and Ratings via Email

Sign-up to receive the latest news and ratings for RNN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:RNN
Previous SymbolNYSEMKT:RNN
CUSIPN/A
Phone+1-240-2685300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees17
OptionableOptionable

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) Frequently Asked Questions

What is Rexahn Pharmaceuticals' stock symbol?

Rexahn Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "RNN."

How were Rexahn Pharmaceuticals' earnings last quarter?

Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) issued its quarterly earnings data on Monday, November, 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.17) by $0.00. View Rexahn Pharmaceuticals' Earnings History.

When is Rexahn Pharmaceuticals' next earnings date?

Rexahn Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Rexahn Pharmaceuticals.

What price target have analysts set for RNN?

4 Wall Street analysts have issued 1-year price objectives for Rexahn Pharmaceuticals' shares. Their forecasts range from $8.00 to $17.00. On average, they anticipate Rexahn Pharmaceuticals' stock price to reach $12.50 in the next twelve months. This suggests a possible upside of 900.0% from the stock's current price. View Analyst Price Targets for Rexahn Pharmaceuticals.

What is the consensus analysts' recommendation for Rexahn Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rexahn Pharmaceuticals in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rexahn Pharmaceuticals.

What are Wall Street analysts saying about Rexahn Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rexahn Pharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and price target of $17. The majority of contribution to our valuation comes from RX-3117, which represents 72% of our $17 price target. The remaining valuation comes from RX-5902 (Supinoxin) for triple negative breast cancer. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (1/15/2019)
  • 2. According to Zacks Investment Research, "REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. " (1/8/2019)

Has Rexahn Pharmaceuticals been receiving favorable news coverage?

Press coverage about RNN stock has been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Rexahn Pharmaceuticals earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days.

Are investors shorting Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,133,185 shares, an increase of 18.0% from the December 14th total of 960,272 shares. Based on an average daily trading volume, of 357,783 shares, the short-interest ratio is presently 3.2 days. Currently, 3.0% of the company's stock are sold short. View Rexahn Pharmaceuticals' Current Options Chain.

Who are some of Rexahn Pharmaceuticals' key competitors?

Who are Rexahn Pharmaceuticals' key executives?

Rexahn Pharmaceuticals' management team includes the folowing people:
  • Dr. Ely Benaim, Chief Medical Officer (Age 57)
  • Dr. Lisa Elizabeth Nolan, Chief Bus. Officer (Age 56)
  • Mr. Douglas J. Swirsky C.F.A., CPA, CPA, CFA, CEO, Pres, CFO, Corp. Sec. & Director (Age 49)
  • Dr. Andrew Eisen M.D., VP of Translational Medicine
  • Dr. Madhukar H. Trivedi M.D., Consultant

How do I buy shares of Rexahn Pharmaceuticals?

Shares of RNN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rexahn Pharmaceuticals' stock price today?

One share of RNN stock can currently be purchased for approximately $1.25.

What is Rexahn Pharmaceuticals' official website?

The official website for Rexahn Pharmaceuticals is https://rexahn.com/cms/.

How can I contact Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals' mailing address is 15245 Shady Grove Rd Ste 455, ROCKVILLE, MD 20850-7203, United States. The company can be reached via phone at +1-240-2685300.


MarketBeat Community Rating for Rexahn Pharmaceuticals (NYSEAMERICAN RNN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  277 (Vote Outperform)
Underperform Votes:  219 (Vote Underperform)
Total Votes:  496
MarketBeat's community ratings are surveys of what our community members think about Rexahn Pharmaceuticals and other stocks. Vote "Outperform" if you believe RNN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RNN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Featured Article: What is a Fiduciary?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel